Send to

Choose Destination
Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6.

Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.

Author information

Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-6942 USA.



2-Deoxy-2-[18F]fluoro-D-Glucose positron emission tomography (FDG-PET) stages patients with Hodgkin's disease (HD) and Non-Hodgkin's lymphoma (NHL) with higher accuracy than computed tomography (CT). We sought to determine whether integrated (hardware) fused PET/CT imaging results in further improvements in staging accuracy.


Seventy-three patients (age 51 +/- 17 years, 37 female, 36 male) with HD (n = 20) or NHL (n = 53) undergoing staging were studied with an integrated PET/CT system. Image findings were verified by clinical follow up, additional imaging and when available, histology.


Thirty-four of 73 patients (46.5%) had evidence of disease and 39 were disease free as confirmed by clinical evaluation and follow-up for 41 +/- 22 weeks (n = 73), including biopsy (n = 26), and other imaging modalities (n = 52) when available. A discordant image interpretation between PET and PET/CT occurred in seven patients (10%). PET/CT correctly upstaged two and downstaged five patients. Overall staging was accurate in 93% with PET/CT and 84% with PET (P = 0.03).


Lymphoma is staged with higher accuracy using PET/CT than PET alone.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center